- Last Updated on Wednesday, 21 October 2015 05:33
PHI's non-destructive test method has the potential to become the quality assurance method of future cell therapies, for millions of patients.
Modern drug research is based on experiments performed on cultured cells. These are treated and analyzed with a variety of established methods. Common to these methods is that they are destructive to the cell. This is a consequence of that living cells are translucent and therefore difficult to see in an ordinary light microscope. This has curiously led to that life's smallest building block – the cell – in general is studied when it is dead.
To view how cells change over time, scientists image living cells over several days, using a microscope. These images are later viewed at a greater pace to observe the slow changes. This method is known as time-lapse microscopy.
Scientists measure cells in a cytometer. However, when measuring cells with a cytometer, the cells must be removed from the cell culture container and destructively stained with toxic stains. This makes conventional cytometers unsuitable to measure cellular development over time. More about time-lapse microscopy…
What we do
PHI leads the ground-breaking development of time-lapse cytometry instrumentation and software. With the first instrument introduced in 2011, the company today offers a range of products for long-term quantitative analysis of living cell dynamics that circumvent the drawbacks of traditional methods requiring toxic stains.
Headquartered in Lund, Sweden, PHI trades through a network of international distributors. Committed to promoting the science and practice of time-lapse cytometry, PHI is actively expanding its customer base and scientific collaborations in cancer research, inflammatory and autoimmune diseases, stem cell biology, gene therapy, regenerative medicine and toxicological studies.
PHI's time-lapse cytometers are based on a novel microscopy technology – holographic microscopy.
The traditional way to create a visual image is to let a camera lens create the image directly onto a light sensitive surface, a photographic film or an image sensor. When images are created in this way, essential information is lost. This makes transparent objects difficult to see, for example, a glass window, an ice cube in a glass of water or a living cell.
In a holographic microscope, images are not created directly on the image sensor. Instead the image sensor captures the light information from the object. This information is processed by a computer to create the visual image. Computer software thus replaces the camera lens and functions as a digital lens, which is adjusted according to the desired visual image in a way that is not possible with a rigid glass lens. This new digital adaptability will fundamentally change the light microscope and thus humanity's ability to observe living cells.
PHI's time-lapse cytometers uses this adaptability to automatically analyze living cells in ways not previously possible. PHI have been granted over 10 patents and have a number of ongoing patent applications. More about holographic microscopy…
PHI's first product, HoloMonitor M3, was launched in 2011. The HoloMonitor M3 is a bench-top time-lapse cytometer equipped with a motorized stage and variable magnification. The Company's second product, HoloMonitor M4, was launched in 2013. The HoloMonior M4 allows for time analysis of living cells directly in the incubator in which they are cultured. PHI's products are distributed through regional distributors in Europe, Asia and North America. More about products…
Customers and markets
PHI's market is the 70 000 cell laboratories in which, among others, cancer- and stem cell researchers are active. Part of the this market is still in a pre-clincal research stage. This sub-market reaches full potential in the event cell therapies becomes a treatment for a range of common diseases.
Cell therapies based on stem cells takes living cells from the patient. These cells are changed, cultured and returned to the patient. PHI's non-destructive test method has the potential to become the quality assurance method of future cell therapies, for millions of patients.
The PHI share is listed on AktieTorget and can be traded online at Avanza, Nordnet or through a broker at your bank. In Sweden AktieTorget is well known for providing investment capital to small developing companies.
There are approximately 130 companies that are traded daily on AktieTorget. Share information of these companies is published daily in all the major Swedish newspapers.
AktieTorget was created in 1998 and has over the years gained acceptance. Today, AktieTorget is a popular way for the general public to invest in small businesses.